Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Major Program

Supportive Care and Symptom Management

NCI Community Oncology Research Program

Research Group

Community Oncology and Prevention Trials

Status

Completed

NCT ID

NCT04600336

This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.

Intervention

Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration

Condition

Prostate Carcinoma

Investigators

Bradley J. Stish, MD

See list of participating sites